The Missing Ingredient for Big Tech's $3T Recipe?

Big Tech doesn't build everything; they buy what's next. And only Emteq's tech offers real behavior insights for smart glasses, key to unlocking the $3T XR market. Their patented sensors track live facial muscle movements. With health-focused smart glasses in demand, only Emteq has this tech.

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Vandana Singh
July 07, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga Pro.

What Happened?

The company reported updated data from the BEACON Phase 1b/2a study of subcutaneous briquilimab in adult chronic spontaneous urticaria (CSU) participants and provided an update on the program. It reported preliminary data in January.

The primary endpoints are briquilimab’s safety and tolerability, and the secondary endpoints are focused on clinical activity and PK/PD.

Also Read: InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

Primary measurements used to assess clinical activity were the sum of the Hives Severity Score and the daily Itch Severity Score (ISS), as measured via the Urticaria Activity Score over 7 days (UAS7) on a 0 to 42-point scale.

Briquilimab administration resulted in disease control in the 240mg and 360mg single-dose cohorts.

Eight of nine (89%) participants enrolled across both cohorts achieved a complete response, and seven of nine (78%) achieved a clinical response by week 2.

Reductions in UAS7 scores were reported with a mean change from baseline at 4 weeks of 28.3 points in the 240mg single-dose cohort and 22.9 points in the 360mg single-dose cohort.

In addition, BEACON participants who rolled over into the open-label extension study dosing at 180mg Q8W demonstrated clinical efficacy with 8 of 11 (73%) participants achieving a complete response at 12 weeks.

Results from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question.

The company is investigating the drug product lot in question. It expects to have the investigation results in the coming weeks.

Key observations noted in those 10 patients were lower than expected drops in mean tryptase levels and no discernable impact on UAS7 scores. The 2 participants enrolled in the cohorts that have been confirmed as being dosed with drug product from a different lot both achieved complete response.

The company also plans to enroll an additional 10-12 patients across the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts to ensure a robust data set to inform the Phase 2b CSU study.

Data from the additional BEACON patients is expected in the fourth quarter of 2025, and commencement of the Phase 2b study is now expected in mid-2026.

The company has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN trial evaluating briquilimab in asthma.

Why It Matters?

To focus resources on advancing briquilimab in CSU, the company is halting the asthma study and pausing development.

In addition, the company is halting development in SCID and will implement several other cost-cutting measures, including a potential restructuring, to extend the runway and reduce expenses.

Briquilimab treatment also resulted in deep and durable disease control in the open-label extension study evaluating briquilimab at 180mg Q8W, with 8 of 11 participants (73%) achieving a complete response at the week 12 assessment.

Substantial reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses. Tryptase levels below the lower limit of quantification were reported for 8 of 10 (80%) participants across the 240mg and 360mg single-dose cohorts.

Briquilimab was tolerated well in the BEACON study and the open-label extension, with no dose-limiting toxicities observed.

Price Action: JSPR stock is down 54.5% at $3.08 at the last check on Monday.

Read Next:

Photo by PeopleImages.com – Yuri A via Shutterstock

Continue Reading...

Popular

Trump keeps saying the GOP mega bill will eliminate taxes on Social Security. It does not

WASHINGTON (AP) — President keeps saying that Republicans' mega legislation will eliminate taxes on federal benefits.

Social Security Administration Sends 'Unbelievable' Email On Trump's 'Big, Beautiful Bill': Report

Email from SSA claims Trump's tax law will eliminate taxes on Social Security benefit. Critics call it politically motivated and incorrect.

This Is the NEXT Palantir - Ad

Forget ChatGPT. Forget Google. The biggest AI winner? Palantir-arming the Pentagon while others chased chatbots. Its stock surged 1,759%. Now Trump's $5.3T "Golden Dome" missile shield is here-and one tiny AI firm is at the center, embedded in 300+ defense programs. Missed Palantir? This is your shot.

A judge resisted Trump’s order on gender identity. The EEOC just fired her

The federal agency charged with protecting workers’ civil rights has terminated a New York administrative judge who , including President Donald Trump’s executive order decreeing male and female as .

Gold Just Hit Another Record. This Junior Could Be Next. - Ad

This copper junior was the smallest company invited to a top global mining conference. With nearly 1B pounds CuEq and 50,000m of funded drilling, this story won't stay quiet for long.

Quantum Stocks Surge And Stumble: Here's What Happened This Week

Quantum Computing announced a $200 million private placement, Microsoft's CEO said quantum computing could take scientific advancements to the next level and more from the week.

Trump's Tariffs, Boeing's Blowout, Tesla's Robotaxi, BYD's European Triumph And GM's Massive Recall: This Week In Mobility

This week's business and finance highlights include Japan's rejection of Trump's auto tariffs, Boeing's scrutiny over a mid-air incident, Tesla's Robotaxi launch, BYD's dominance in Europe, and GM's massive vehicle recall.

Copper's Rally Is Back. This $31M Junior Is Sitting on a Potential Fortune - Ad

A high-grade copper-gold discovery in Quebec just delivered extremely high grade intercepts. Valuation? Just $31M. With copper breaking out, the timing here could be perfect. Get the symbol here.

North Koreans swim and play at a beach resort touted as a boost for tourism

SEOUL, South Korea (AP) — North Koreans swam, rode water park slides and enjoyed other water activities at a newly opened state media reported Wednesday, as the country largely maintains a ban on the entry of foreign tourists.

Cargo ship carrying new vehicles to Mexico sinks in the North Pacific weeks after catching fire

ANCHORAGE, Alaska (AP) — A cargo ship that had been delivering new vehicles to Mexico sank in the North Pacific Ocean, weeks after crew members abandoned ship when they couldn’t extinguish an onboard fire that left the carrier dead in the water.

Copper's Spiking - And This Junior Has the Grades to Match - Ad

Copper is climbing again - and this time, it looks tariff-proof. A $31M junior just posted nearly 1B lbs of copper equivalent. With insiders and institutions piling in, this could be the next breakout.

Trump ramps up attacks on the Federal Reserve but Powell sticks to 'wait and see' stance

WASHINGTON (AP) — Federal Reserve Chair Jerome Powell on Tuesday stuck to that the central bank will keep its key rate on hold while it waits to see how President Donald Trump's effect the economy, despite the from the White House, which wants lower borrowing costs.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

What's in the latest version of Trump's big bill moving through the Senate

WASHINGTON (AP) — Republicans are inching closer to getting their tax and spending cut bill through Congress with a final Senate vote likely late Monday or early Tuesday.

Mexican banks face cascading consequences following US sanctions

Mexico City (AP) — Three Mexican financial institutions sanctioned by the Trump administration last week have felt a cascade of economic consequences following the allegations that they helped launder millions of dollars for drug cartels.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.

These are the celebs who are attending Jeff Bezos’ Venice wedding

VENICE, Italy (AP) — arrived in Venice on Thursday, leading a star-studded guest list of celebrities descending on the lagoon city for the weekend wedding of Amazon founder Jeff Bezos and Lauren Sánchez.

The Unlikely Duo Rethinking Wearable Technology - Ad

Why did a surgeon and Snap exec team up? They saw the missing ingredient in the $84T wearables market: behavior. So they built Emteq and invented smart glasses sensors to track real-time expressions, unlocking insights into why we do things. With a $15M term sheet already secured, Emteq is what Big Tech's missing.

This Stock Just Popped 30% In 5 Days — Now Expert Says It 'Looks Potentially Explosive'

Experts have been betting on the growth prospects of Oscar Health, as it surged by 16.51% on Wednesday and 32.56% in the last five days.

How to manage ADHD at work and turn it into a strength

NEW YORK (AP) — Jeremy Didier had taken her son to a psychologist for a when she spotted an article about women with the condition. As she read it in the waiting room, she thought to herself: They're describing me.

FDA Submission Expected This Summer - Invest Before It Happens - Ad

This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.

Diddy Jury Deadlocked On Racketeering Conspiracy Charge As Verdicts Reached On Sex Trafficking Counts — Jurors To Return Wednesday

Jurors in Sean "Diddy" Combs' trial reached verdicts on four charges related to sex trafficking but remain deadlocked on the racketeering conspiracy charge, with deliberations set to continue.

Back This Medical AI Tech - Ad

You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.

Autonomous Vehicles Hit Their 'ChatGPT Moment' — Best Stocks To Watch Now

Autonomous vehicles are entering their ‘ChatGPT moment' as AI unlocks real-world deployment. Discover 28 top stocks in a $1.2 trillion market.

A hard-right lawmaker is sworn in as Greece's migration minister

ATHENS, Greece (AP) — A hard-right lawmaker was sworn in Monday as Greece’s migration minister, replacing a fellow right-wing political heavyweight who resigned following

The Missing Ingredient for Big Tech's $3T Recipe? - Ad

Big Tech doesn't build everything; they buy what's next. And only Emteq's tech offers real behavior insights for smart glasses, key to unlocking the $3T XR market. Their patented sensors track live facial muscle movements. With health-focused smart glasses in demand, only Emteq has this tech.

Royal Caribbean Cruises Stock Up 0.9% After Key Trading Signal

A significant trading signal occurred for Royal Caribbean Cruises stock at a price of $331.57, after which RCL rose up to 0.9%.

This Is the NEXT Palantir - Ad

Forget ChatGPT. Forget Google. The biggest AI winner? Palantir-arming the Pentagon while others chased chatbots. Its stock surged 1,759%. Now Trump's $5.3T "Golden Dome" missile shield is here-and one tiny AI firm is at the center, embedded in 300+ defense programs. Missed Palantir? This is your shot.

Trump's Crypto Ventures, Draper And Cathie Wood's Bitcoin Predictions, MSTR Estimates, And More: This Week In Crypto

The past week in the world of cryptocurrency was nothing short of eventful. From legislative moves aimed at curbing alleged corruption in cryptocurrency ventures to bold predictions about Bitcoin’s dominance, the week was filled with intriguing developments. Here’s a quick recap of the top stories that made headlines.

Judge allows antitrust lawsuit against Apple to proceed

A federal judge on Monday rebuffed Apple's request to throw out a U.S. government lawsuit alleging the technology trendsetter has built a maze of illegal barriers to protect the iPhone from competition and fatten its profit margins.

Gold Just Hit Another Record. This Junior Could Be Next. - Ad

This copper junior was the smallest company invited to a top global mining conference. With nearly 1B pounds CuEq and 50,000m of funded drilling, this story won't stay quiet for long.

Dave Ramsey Says Real Estate Can Outperform Stocks, But Warned That Higer Returns 'Don't Come Free'

Dave Ramsey said real estate can outperform stocks with higher returns due to its imperfect market and multiple income streams, but warned it requires significantly more time, effort, and risk to manage effectively.

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

NEW YORK (AP) — Anne Wojcicki's bid to buy , the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight.

Copper's Rally Is Back. This $31M Junior Is Sitting on a Potential Fortune - Ad

A high-grade copper-gold discovery in Quebec just delivered extremely high grade intercepts. Valuation? Just $31M. With copper breaking out, the timing here could be perfect. Get the symbol here.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service